Tapering Strips: How European Pharmacies Enable Microdose Reductions

Tapering strips are pre-packaged daily dose units, compounded by specialty pharmacies, that step a patient down through arithmetic or hyperbolic dose reductions far smaller than commercially available tablet strengths permit. They originated in the Netherlands in 2013 through the collaboration between psychiatrist Peter Groot, the Maastricht University Medical Center user research group, and the Regenboog Apotheek (Bavel), and have since become the practical reference standard for executing the slow, non-linear tapers recommended by Horowitz and Taylor in the Maudsley Deprescribing Guidelines. For prescribers outside the EU who treat patients with severe protracted withdrawal or who fail conventional dose reductions, understanding what tapering strips are — and how to replicate their pharmacology with locally available compounding — is increasingly part of standard psychiatric and primary care practice.

What a tapering strip actually is

A tapering strip is a roll or pouch series of 28 daily-dose sachets. Each sachet contains a single, precisely compounded oral dose of the index drug. Across the 28 days, the daily dose decreases in defined increments — most commonly 5% to 10% of the prior day's dose, but customizable down to roughly 0.5 mg or smaller fractional steps for drugs like paroxetine, venlafaxine, citalopram, and clonazepam.

Strips are produced by compounding pharmacies — the most cited being Regenboog Apotheek (the Netherlands) — under prescription from a clinician who specifies:

1. The active drug and starting dose.
2. The target ending dose (often zero, sometimes a maintenance dose).
3. The reduction percentage per step (commonly 10% hyperbolic; or 5% for sensitive patients).
4. The duration of the strip (typically 28 days, occasionally 56).
5. Whether the schedule should be arithmetic (equal mg decrements) or hyperbolic (equal receptor occupancy decrements).

The patient receives a calendar-style strip, opens one sachet per day, and at the end of 28 days returns to the prescriber to assess withdrawal severity. A new strip is dispensed for the next 28 days at the appropriate continuation dose. If symptoms emerge mid-strip, the patient pauses at the most recently tolerated dose rather than reverting to the original; subsequent strips are recalibrated.

The unit cost in the Netherlands is approximately €40–€135 per 28-day strip depending on the drug and dose complexity, and was reimbursed by Dutch statutory health insurance after a 2022 ruling, with continuing legal disputes in 2024–2025 over scope.

The pharmacological rationale: hyperbolic dose-response

The clinical case for tapering strips rests on the now well-established hyperbolic relationship between SSRI/SNRI dose and serotonin transporter (SERT) occupancy, demonstrated by PET imaging studies (Meyer et al., Am J Psychiatry, 2004; Sørensen et al., 2022). At standard therapeutic doses of citalopram 20 mg, paroxetine 20 mg, or sertraline 50 mg, SERT occupancy is approximately 80%. Halving the dose typically reduces occupancy by only 4–8 percentage points. The receptor occupancy curve flattens markedly at the top and steepens dramatically near zero, such that going from 5 mg paroxetine to 2.5 mg removes roughly the same proportion of remaining occupancy as going from 20 mg to 10 mg.

The clinical consequence is that linear taper schedules — for example, 20 → 15 → 10 → 5 → 0 mg in equal mg increments every two weeks — front-load the small end of the curve with the largest receptor changes. Most discontinuation syndromes occur in the final steps, when prescribers and patients incorrectly assume the worst is behind them.

Hyperbolic tapering inverts the schedule. Reductions are large early (when receptor occupancy changes are small) and small late (when each milligram represents a disproportionate occupancy change). A 10% reduction of the current dose at every step — the default offered by Dutch tapering strip pharmacies — yields a smooth, exponential descent. For paroxetine 20 mg, a 10% hyperbolic schedule produces approximately: 20 → 18 → 16.2 → 14.6 → 13.1 → 11.8 → 10.6 → 9.5 → 8.6 → 7.7 → 6.9 → 6.2 → 5.6 → 5 → 4.5 → 4.1 → 3.7 → 3.3 → 3.0 → 2.7 → 2.4 → 2.2 → 1.9 → 1.7 → 1.6 → 1.4 → 1.3 → 1.2 (and onward, by step or month, depending on tolerability).

Commercial paroxetine in most jurisdictions is available only as 10, 20, 30, and 40 mg tablets, with a 10 mg/5 mL oral suspension in some markets. There is no commercial formulation that allows the 0.5–2 mg precision required at the low end of a hyperbolic taper. Tapering strips fill this gap.

Evidence base for tapering strips

The principal published evidence comes from a series of survey and observational studies from the Groot/Van Os group in the Netherlands.

| Study | Year | Drug | Sample | Result | ||---|---|---| | Groot & van Os, Ther Adv Psychopharmacol | 2018 | Venlafaxine | n=895 | 71% completed full taper using strips after prior failed attempts; mean taper duration 56 days | | Groot & van Os, Ther Adv Psychopharmacol | 2020 | Paroxetine, venlafaxine | n=1,194 | Patients who had previously failed conventional discontinuation achieved successful taper rates of 64–71% | | Horowitz & Taylor, Lancet Psychiatry | 2019 | All SSRIs/SNRIs | Review | Established the receptor-occupancy basis for hyperbolic tapering | | Sørensen, Rüdinger, et al., JAMA Psychiatry | 2022 | SSRIs | Meta-analysis | Confirmed incidence and severity of withdrawal; recommended slow hyperbolic taper | | Framer, Ther Adv Psychopharmacol | 2021 | All SSRIs | Clinical guide | Reproduces hyperbolic schedules without proprietary strips |

The Groot studies are limited by self-selection — patients seeking tapering strips have already failed conventional discontinuation — and by lack of a control arm. They cannot, on their own, establish that strips are superior to a comparably slow hyperbolic schedule executed with liquid formulations or compounded capsules. What they do establish is that patients in whom standard tapering has failed can succeed when given precise micro-dose control over a prolonged period.

The 2024 Maudsley Deprescribing Guidelines cite this evidence and recommend hyperbolic tapers reaching final doses of approximately 1–5% of the original therapeutic dose before discontinuation — a precision that, in practice, requires either tapering strips, compounded capsules, liquid suspensions, or weighed bead counts.

Why tapering strips remain Europe-centric

Tapering strips have not been broadly adopted outside the EU for three reasons:

1. Regulatory framework for magistral compounding. Under EU Directive 2001/83/EC, member states permit pharmacist-compounded magistral preparations for individual patients. The Netherlands, Germany, Belgium, and the UK have functioning specialty compounding sectors. US law permits 503A compounding under FDA oversight, but interstate shipment is restricted, and most US compounding pharmacies do not produce daily-dose strip packaging.
2. Insurance reimbursement. The 2022 Dutch ruling — that strips constitute medically necessary care reimbursable under the Zorgverzekeringswet — is unusual. In most jurisdictions, patients pay out-of-pocket. The €40–€135 per month cost is a barrier in fee-for-service systems.
3. Prescriber familiarity. Most psychiatrists outside Europe were trained to use the FDA-approved label tapers (e.g., paroxetine 20 → 10 → 0 over 7–14 days). The hyperbolic framework requires learning a new schedule, and few formularies link it to a dispensable product.

Replicating tapering strip pharmacology without strips

For prescribers in the US, Canada, Australia, and other jurisdictions where Dutch tapering strips are not directly accessible, several practical substitutes deliver equivalent precision.

Liquid formulations

• Paroxetine oral suspension (10 mg/5 mL) allows dosing to 0.5 mg using a 1 mL oral syringe.
• Sertraline oral concentrate (20 mg/mL) similarly permits microdose precision.
• Citalopram oral solution (10 mg/5 mL) and escitalopram oral drops (20 mg/mL).
• Fluoxetine oral solution (20 mg/5 mL) is least often needed (long half-life of norfluoxetine smooths the taper passively), but useful when finer steps are wanted.
• Venlafaxine has no licensed liquid in most markets, requiring bead counting or compounding.
• Risperidone oral solution (1 mg/mL).

A practical 10% hyperbolic schedule for paroxetine using the oral suspension might step from 20 mg → 18 → 16.2 → 14.6 mg at 4-week intervals using a 1 mL syringe drawing from the suspension, with each volume calculated by the dispensing pharmacist on a printed schedule.

Compounded capsules

503A compounders in the US can prepare capsules at any specified mg value (e.g., paroxetine 1.5 mg, venlafaxine 12.5 mg, clonazepam 0.125 mg). For tapers requiring more than 8–10 unique strengths, this is workflow-heavy. Some prescribers issue prescriptions for graduated "compounding kits" with all monthly steps prepared at once.

Tablet splitting, bead counting, and weighing

For drugs without liquid or compounding options, patients can:

• Split scored tablets with a pill cutter — practical only down to about a quarter of the smallest commercial dose.
• Open capsule formulations of venlafaxine XR, duloxetine, or desvenlafaxine, count or weigh the beads, and re-encapsulate. A digital jewelry scale (0.001 g precision) is required for reproducibility. This is the method described in the Surviving Antidepressants and Inner Compass community resources, and reproduced in Framer (2021).
• Dissolve a tablet in a known volume of water and draw a measured aliquot — feasible for some immediate-release formulations but creates uncertainty about uniform suspension.

The pharmacology is identical to a tapering strip when executed precisely. The clinical limitation is patient adherence: counting dozens of beads daily is not realistic for many patients with comorbid depression or anxiety.

Direct import

Some Dutch and Belgian pharmacies will ship strips internationally with an EU prescription; some accept prescriptions from non-EU clinicians under personal-import allowances. Customs treatment varies by country, and this is not a recommended primary strategy for routine practice.

Drugs most commonly dispensed as strips

The Regenboog Apotheek public catalog and the Groot 2020 publication list the most-requested strips. These map onto the drugs with the most severe documented withdrawal syndromes and the largest gaps between commercial dose strengths.

Drug	Reason strips are requested
Paroxetine	Severe withdrawal; short half-life (~21 h); no parent-drug active metabolite
Venlafaxine IR/XR	Very short effective half-life (~5 h IR); bead-form makes self-tapering difficult
Duloxetine	Severe sensory and dysautonomia symptoms reported; capsule with enteric-coated beads
Citalopram, escitalopram	Common reductions to 1–2 mg final step required
Sertraline	Less severe withdrawal but smooth hyperbolic descent often requested
Mirtazapine	Sedation-rebound and pruritus reported below 7.5 mg
Clonazepam, diazepam, lorazepam	Benzodiazepine tapers per Ashton Manual, often co-managed with crossover to diazepam
Pregabalin, gabapentin	Severe withdrawal with abrupt discontinuation; FDA label is silent on protocol
Quetiapine	Sleep-rebound and akathisia below 25–50 mg

The Ashton Manual remains the dominant reference for benzodiazepine tapers; tapering strips are often used to execute the slow distal portion of an Ashton schedule (the final 10–20% of dose) where commercial tablet strengths run out.

Indications and counter-indications

Tapering strips — or equivalent precision tapering — should be considered when:

• A patient has failed one or more conventional taper attempts and re-experienced withdrawal.
• The patient is on a short-half-life agent (paroxetine, venlafaxine IR, duloxetine, immediate-release benzodiazepines).
• The patient has been on the drug for more than 1–2 years, particularly with prior dose increases or multiple medications.
• The patient is poly-medicated and a sequenced deprescribing plan is being executed.
• The patient reports sensitivity to small dose changes during a prior taper.

Strips are not first-line for every discontinuation. Patients who have been on an SSRI for less than 6–12 months at low doses can often discontinue over 4–8 weeks using commercial tablet strengths and liquid for the final step. Reserving the slow hyperbolic protocol for higher-risk patients is reasonable. The corollary is that prescribers should ask explicitly about prior taper attempts and tolerance before re-starting a standard schedule that has already failed.

Documentation and communication

A useful prescriber note when initiating a strip-based or strip-equivalent taper:

• Drug, current dose, duration on current dose, total duration on the medication class.
• Reason for discontinuation (no longer indicated, side-effect burden, patient preference, pregnancy planning, etc.).
• Prior taper attempts and outcomes.
• Schedule: percentage reduction per step, step interval, target end dose, expected duration of full taper.
• Method of dose delivery (strip, liquid, compounded capsule, weighed beads).
• Re-instatement plan if severe withdrawal emerges: typically return to last tolerated dose and hold for at least four weeks.

Patient-facing communication can use neutral framing: "We are going to reduce your dose in very small steps over several months. The schedule looks unusually slow on paper, but it is what the current evidence supports for people in your situation. If at any point the steps feel too aggressive, we will hold or adjust."

Clinical pearls

• A hyperbolic step from the current dose, repeated at a 2–4 week interval, is the default starting protocol. Adjust the step size and the interval downward for patients with documented withdrawal sensitivity.
• The hardest part of every taper is below 5 mg paroxetine-equivalent. Plan for 2–4 months at the lowest doses, and have a liquid or compounded formulation ready before the patient runs out of commercial strengths.
• If withdrawal emerges, reinstate the last tolerated dose, hold for at least 4 weeks, then resume at a smaller step size. Do not increase to the original starting dose unless symptoms are severe and disabling.
• For venlafaxine, duloxetine, and other bead-formulation drugs, request a compounded capsule rather than asking the patient to count beads daily.
• Document the schedule in writing — printed and dated — and review it at each visit. Tapering strips work in part because the schedule is physically embodied in the strip; equivalent paper schedules need the same level of explicitness.
• The most common reason a taper fails is that the prescriber follows the FDA label rather than the receptor-occupancy curve. Read Horowitz and Taylor, 2019, before designing a long-term discontinuation plan.

---

For more clinician resources on safe deprescribing and tapering, visit tapermeds.com.